Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ying ZhaoSean Wasserman

Abstract

Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy and safety of this strategy is unknown. In this retrospective cohort study adults receiving bedaquiline substitution for MDR tuberculosis therapy, plus a matched control group who did not receive bedaquiline, were identified from the electronic tuberculosis register in the Western Cape Province, South Africa. The primary outcome measure was the proportion of patients with death, loss to follow-up, or failure to achieve sustained culture conversion at 12 months of treatment. Data from 162 patients who received bedaquiline substitution and 168 controls were analyzed; 70.6% were infected with human immunodeficiency virus. Unfavorable outcomes occurred in 35 of 146 (23.9%) patients in the bedaquiline group versus 51 of 141 (36.2%) in the control group (relative risk, 0.66; 95% confidence interval, .46 -.95). The number of patients with culture reversion was lower in those receiving bedaquiline (1 patient; 0.8%) than in controls (12 patients; 10.3%; P = .001). Delayed initiation of bedaquiline was independently associated with failure to achieve sustained culture conversion (ad...Continue Reading

References

Jun 6, 2009·The New England Journal of Medicine·Andreas H DiaconDavid F Mc Neeley
Mar 13, 2010·American Journal of Respiratory and Critical Care Medicine·Doh Hyung KimTae Sun Shim
Sep 7, 2012·PLoS Medicine·Shama D AhujaUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Oct 27, 2012·The European Respiratory Journal·Dennis FalzonUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Jan 10, 2013·Anaesthesia·A M-H HoM K Karmakar
May 27, 2014·The Journal of Antimicrobial Chemotherapy·R P G van HeeswijkR M W Hoetelmans
Aug 20, 2014·Infectious Diseases and Therapy·Gregory J Fox, Dick Menzies
Aug 21, 2014·The New England Journal of Medicine·Andreas H DiaconUNKNOWN TMC207-C208 Study Group
Oct 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lorenzo GuglielmettiUNKNOWN MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Coh
Jul 15, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N NdjekaY Pillay
Dec 10, 2015·The European Respiratory Journal·Alexander S PymUNKNOWN TMC207-C209 Study Group
Jan 23, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M BonnetF Varaine
Sep 3, 2016·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
Sep 15, 2016·The New England Journal of Medicine·Gunar GüntherUNKNOWN for TBNET
Feb 25, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L GuglielmettiJ Furin
Mar 24, 2017·The European Respiratory Journal·Mayara Lisboa BastosDick Menzies
May 23, 2017·The European Respiratory Journal·Lorenzo Guglielmetti
Aug 2, 2017·Vaccine· World Health Organization
Aug 30, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Keertan DhedaChristoph Lange
Sep 1, 2018·The Lancet Child & Adolescent Health· The Lancet Child Adolescent Health

❮ Previous
Next ❯

Citations

Mar 23, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mathieu BastardAlex Telnov
May 14, 2019·The Journal of Antimicrobial Chemotherapy·Sean WassermanGraeme Meintjes
Jul 24, 2020·Future Microbiology·Lorenzo GuglielmettiJérôme Robert
May 31, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Emanuele PontaliUNKNOWN and the writing group members of the Global TB Network Clinical Trials Committee
Apr 20, 2019·Emerging Infectious Diseases·Lawrence MbuagbawChristian Lienhardt
Aug 18, 2021·Expert Opinion on Pharmacotherapy·Ginenus FekaduJoyce H S You
Apr 22, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James C M BrustGraeme Meintjes
Sep 6, 2019·The Lancet. Respiratory Medicine·Keertan DhedaUNKNOWN Lancet Respiratory Medicine drug-resistant tuberculosis Commission group
Jun 19, 2021·The European Respiratory Journal·Palwasha Y KhanCarole D Mitnick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.